Inmolecule Nanotech (XPAR:MLINA) EBITDA Margin %: 1.87% (As of Dec. 2024)


XPAR:MLINA Inmolecule Nanotech SA XPAR:MLINA
6 GF Score
Price €4.08
! 2 Warning Signs
View Full Analysis

What is Inmolecule Nanotech EBITDA Margin %?

Inmolecule Nanotech XPAR:MLINA 6 EBITDA Margin % is 1.87% as of Dec. 2024. GuruFocus rates XPAR:MLINA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Inmolecule Nanotech ranks better than 68.37% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Inmolecule Nanotech's EBITDA for the six months ended in Dec. 2024 was €0.04 Mil. Inmolecule Nanotech's Revenue for the six months ended in Dec. 2024 was €1.98 Mil. Therefore, Inmolecule Nanotech's EBITDA margin for the quarter that ended in Dec. 2024 was 1.87%.

Inmolecule Nanotech  (XPAR:MLINA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Inmolecule Nanotech EBITDA Margin % Related Terms

Inmolecule Nanotech EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Inmolecule Nanotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inmolecule Nanotech EBITDA Margin % Chart

Inmolecule Nanotech Annual Data
Trend Dec23 Dec24
EBITDA Margin %
-88.28 1.87

Inmolecule Nanotech Semi-Annual Data
Dec23 Dec24
EBITDA Margin % -88.28 1.87

XPAR:MLINA vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Inmolecule Nanotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inmolecule Nanotech EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inmolecule Nanotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Inmolecule Nanotech's EBITDA Margin % falls into.


XPAR:MLINA
6GF Score
Inmolecule Nanotech SA XPAR:MLINA
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inmolecule Nanotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Inmolecule Nanotech's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=0.037/1.981
=1.87 %

Inmolecule Nanotech's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=0.037/1.981
=1.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 1.87% mean?
Inmolecule Nanotech (XPAR:MLINA) has a EBITDA Margin % of 1.87% as of Dec. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Inmolecule Nanotech and its competitors. According to the industry distribution chart, Inmolecule Nanotech ranks #298 out of 942 companies in the Biotechnology industry, placing it in the top 31.6%.
Is Inmolecule Nanotech's EBITDA Margin % too high?
Inmolecule Nanotech's current EBITDA Margin % is 1.87%. Based on the distribution chart, Inmolecule Nanotech ranks #298 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Inmolecule Nanotech has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inmolecule Nanotech ranks #298 out of 942 companies for EBITDA Margin %. This puts Inmolecule Nanotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Inmolecule Nanotech and its competitors. Inmolecule Nanotech's current EBITDA Margin % is 1.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (XPAR:MLINA) has a current EBITDA Margin % of 1.87%. The current EBITDA Margin % is 1.87%. Inmolecule Nanotech's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Inmolecule Nanotech (XPAR:MLINA), the current EBITDA Margin % is 1.87% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inmolecule Nanotech Business Description

Address Paseo de la Castellana 91, 4th Floor, Madrid, ESP, 28046
Inmolecule Nanotech SA is a research and development company. The company provides health care, home care and personal care products.
6GF Score

Get the complete analysis for XPAR:MLINA

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price